cetuximab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
chimeric origin	4954	205923-56-4

Description:

Molecule	Description
Synonyms: cetuximab cetuximab (genetical recombination) erbitux C-225 IMC-C225	A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

cetuximab
cetuximab (genetical recombination)
erbitux
C-225
IMC-C225

A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company
July 16, 2008	PMDA	Merck
Feb. 12, 2004	FDA	IMCLONE
June 29, 2004	EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis acneiform	402.33	23.10	107	11477	3950	50589590
Mucosal inflammation	192.92	23.10	118	11466	40024	50553516
Diarrhoea	187.82	23.10	413	11171	588063	50005477
Neutropenia	181.34	23.10	195	11389	147770	50445770
Malignant neoplasm progression	168.27	23.10	133	11451	67991	50525549
Dehydration	157.77	23.10	184	11400	152265	50441275
Hypomagnesaemia	134.57	23.10	77	11507	23079	50570461
Skin toxicity	120.58	23.10	42	11542	3871	50589669
Rash	116.85	23.10	287	11297	437184	50156356
Drug ineffective	100.02	23.10	32	11552	819301	49774239
Paronychia	99.67	23.10	38	11546	4526	50589014
Vomiting	95.27	23.10	275	11309	460483	50133057
Disease progression	92.85	23.10	112	11472	95754	50497786
Infusion related reaction	76.29	23.10	138	11446	169419	50424121
Nausea	73.78	23.10	337	11247	705061	49888479
Pulmonary embolism	73.73	23.10	103	11481	101601	50491939
Radiation skin injury	72.57	23.10	20	11564	843	50592697
Stomatitis	69.56	23.10	100	11484	101244	50492296
Hypokalaemia	66.59	23.10	91	11493	87901	50505639
Serous retinal detachment	63.81	23.10	14	11570	223	50593317
Dermatitis	63.58	23.10	40	11544	14211	50579329
Skin fissures	56.23	23.10	31	11553	8637	50584903
Palmar-plantar erythrodysaesthesia syndrome	55.54	23.10	42	11542	20056	50573484
Arthralgia	55.34	23.10	16	11568	438686	50154854
Metastases to lung	49.33	23.10	31	11553	10989	50582551
Febrile neutropenia	47.08	23.10	82	11502	97585	50495955
Pyrexia	46.63	23.10	191	11393	380012	50213528
Haematotoxicity	42.51	23.10	25	11559	7870	50585670
Thrombocytopenia	40.62	23.10	90	11494	127583	50465957
Deep vein thrombosis	38.55	23.10	64	11520	73240	50520300
Skin reaction	38.37	23.10	27	11557	11541	50581999
Chills	36.36	23.10	73	11511	96614	50496926
Anaemia	35.90	23.10	133	11451	252323	50341217
Decreased appetite	35.67	23.10	114	11470	200809	50392731
Neutrophil count decreased	33.88	23.10	47	11537	45979	50547561
Multiple-drug resistance	33.55	23.10	16	11568	3298	50590242
Weight increased	32.50	23.10	4	11580	201887	50391653
Trichomegaly	32.08	23.10	6	11578	40	50593500
Hypertrichosis	31.73	23.10	11	11573	998	50592542
Rash pustular	30.95	23.10	19	11565	6462	50587078
Ileus	30.82	23.10	25	11559	13204	50580336
Leukopenia	30.33	23.10	55	11529	67473	50526067
Abdominal discomfort	29.98	23.10	8	11576	231633	50361907
Dyspnoea	29.49	23.10	220	11364	547388	50046152
Renal tubular disorder	28.50	23.10	13	11571	2424	50591116
Asthenia	28.40	23.10	146	11438	318896	50274644
Anastomotic leak	27.55	23.10	8	11576	408	50593132
Stress cardiomyopathy	27.54	23.10	19	11565	7868	50585672
Dry skin	27.25	23.10	41	11543	43150	50550390
Drug hypersensitivity	26.75	23.10	12	11572	250998	50342542
Dysphagia	26.17	23.10	56	11528	77462	50516078
Interstitial lung disease	26.06	23.10	45	11539	53131	50540409
Sinusitis	25.98	23.10	4	11580	170554	50422986
Acne	25.97	23.10	27	11557	19568	50573972
Drug intolerance	25.77	23.10	9	11575	219095	50374445
Hypocalcaemia	25.37	23.10	31	11553	26785	50566755
Bone marrow failure	24.63	23.10	31	11553	27593	50565947
Abdominal pain	24.51	23.10	113	11471	236115	50357425
Product dose omission issue	24.45	23.10	6	11578	183832	50409708
Nail disorder	24.01	23.10	19	11565	9689	50583851
Drug interaction	23.82	23.10	8	11576	199613	50393927
Metastases to liver	23.64	23.10	26	11558	20078	50573462
Chemical burns of eye	23.13	23.10	5	11579	74	50593466

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis acneiform	858.66	19.07	272	23167	5219	29545869
Infusion related reaction	451.42	19.07	331	23108	43555	29507533
Mucosal inflammation	432.17	19.07	284	23155	31311	29519777
Hypomagnesaemia	288.46	19.07	177	23262	17291	29533797
Anaphylactic reaction	276.50	19.07	205	23234	27368	29523720
Rash	267.10	19.07	511	22928	189308	29361780
Dehydration	264.82	19.07	386	23053	114362	29436726
Skin toxicity	264.81	19.07	103	23336	3668	29547420
Radiation skin injury	247.14	19.07	65	23374	615	29550473
Paronychia	219.25	19.07	84	23355	2869	29548219
Stomatitis	186.98	19.07	186	23253	36927	29514161
Malignant neoplasm progression	167.91	19.07	247	23192	73612	29477476
Drug ineffective	139.67	19.07	57	23382	363113	29187975
Neutropenia	124.05	19.07	302	23137	131409	29419679
Dysphagia	119.44	19.07	180	23259	54746	29496342
Chills	108.47	19.07	199	23240	71101	29479987
Acne	102.42	19.07	73	23366	9147	29541941
Hypotension	102.29	19.07	362	23077	193992	29357096
Hypersensitivity	97.85	19.07	161	23278	52742	29498346
Diarrhoea	94.81	19.07	515	22924	332183	29218905
Pharyngeal inflammation	94.17	19.07	26	23413	300	29550788
Palmar-plantar erythrodysaesthesia syndrome	91.44	19.07	83	23356	14676	29536412
Drug interaction	87.82	19.07	24	23415	197361	29353727
Flushing	74.64	19.07	103	23336	28889	29522199
Vomiting	74.62	19.07	349	23090	211911	29339177
Erythema	73.84	19.07	176	23263	75430	29475658
Dermatitis	71.46	19.07	55	23384	7743	29543345
Skin reaction	70.91	19.07	44	23395	4373	29546715
Skin fissures	70.52	19.07	42	23397	3877	29547211
Conjunctivitis	70.23	19.07	55	23384	7943	29543145
Decreased appetite	65.67	19.07	258	23181	145084	29406004
Nausea	63.71	19.07	419	23020	288836	29262252
Rash pustular	63.58	19.07	42	23397	4649	29546439
Arthralgia	62.00	19.07	17	23422	139600	29411488
Radiation mucositis	58.40	19.07	15	23424	128	29550960
Hypocalcaemia	57.10	19.07	76	23363	20589	29530499
Oxygen saturation decreased	53.22	19.07	113	23326	44824	29506264
Pain in extremity	51.80	19.07	12	23427	110421	29440667
Product dose omission issue	50.44	19.07	8	23431	96375	29454713
Pulmonary embolism	49.40	19.07	153	23286	76381	29474707
Fall	49.16	19.07	41	23398	177137	29373951
Pulse absent	48.91	19.07	37	23402	5076	29546012
Device related infection	48.67	19.07	61	23378	15575	29535513
Pyrexia	48.50	19.07	391	23048	287231	29263857
Toxicity to various agents	48.41	19.07	40	23399	173621	29377467
Anaphylactic shock	47.99	19.07	56	23383	13280	29537808
Dyspnoea	47.66	19.07	430	23009	326302	29224786
Disease progression	46.74	19.07	157	23282	81759	29469329
Folliculitis	45.90	19.07	32	23407	3868	29547220
Pruritus	44.54	19.07	197	23242	116652	29434436
Onycholysis	43.70	19.07	16	23423	480	29550608
Condition aggravated	42.90	19.07	32	23407	146263	29404825
Gastrointestinal toxicity	41.40	19.07	24	23415	2107	29548981
Dry skin	40.46	19.07	69	23370	23238	29527850
Ileus	39.83	19.07	53	23386	14349	29536739
Leukopenia	39.03	19.07	114	23325	55089	29495999
Insomnia	39.01	19.07	11	23428	88750	29462338
Proteus infection	38.09	19.07	17	23422	858	29550230
Neutrophil count decreased	37.81	19.07	97	23342	43470	29507618
Neuropathy peripheral	36.91	19.07	132	23307	70895	29480193
Blood magnesium decreased	36.71	19.07	32	23407	5362	29545726
Alopecia	36.48	19.07	59	23380	19025	29532063
Blood pressure immeasurable	35.67	19.07	16	23423	817	29550271
Tumour haemorrhage	35.51	19.07	23	23416	2462	29548626
Interstitial lung disease	35.03	19.07	113	23326	57605	29493483
Gait disturbance	34.32	19.07	8	23431	73341	29477747
Clostridial infection	33.96	19.07	25	23414	3290	29547798
Febrile neutropenia	33.90	19.07	177	23262	112063	29439025
Neoplasm progression	33.49	19.07	56	23383	18556	29532532
Cardio-respiratory arrest	33.40	19.07	102	23337	50499	29500589
Nail dystrophy	32.98	19.07	10	23429	164	29550924
Urticaria	32.26	19.07	106	23333	54554	29496534
Blood pressure decreased	32.22	19.07	94	23345	45383	29505705
Thrombocytopenia	31.78	19.07	199	23240	134624	29416464
Serous retinal detachment	31.36	19.07	12	23427	408	29550680
Nasopharyngitis	31.09	19.07	5	23434	59660	29491428
Weight increased	31.02	19.07	11	23428	76656	29474432
Pneumatosis intestinalis	30.46	19.07	23	23416	3146	29547942
Peripheral swelling	29.72	19.07	7	23432	63732	29487356
Nail disorder	28.85	19.07	18	23421	1806	29549282
Necrotising oesophagitis	28.83	19.07	12	23427	510	29550578
Cardiac failure congestive	27.71	19.07	13	23426	76568	29474520
Myalgia	27.67	19.07	12	23427	74007	29477081
Headache	27.28	19.07	61	23378	173946	29377142
Oesophagitis	27.19	19.07	40	23399	11883	29539205
White blood cell count decreased	26.93	19.07	134	23305	83228	29467860
Laryngeal oedema	26.84	19.07	21	23418	3027	29548061
Prothrombin level decreased	26.26	19.07	14	23425	1044	29550044
Hospitalisation	25.98	19.07	3	23436	45985	29505103
Induration	25.79	19.07	13	23426	863	29550225
Monocytopenia	25.57	19.07	7	23432	78	29551010
Coronary artery disease	24.67	19.07	3	23436	44187	29506901
Anxiety	24.58	19.07	19	23420	85346	29465742
Aspiration	24.44	19.07	35	23404	10145	29540943
Hypophagia	24.13	19.07	52	23387	20820	29530268
Embolism	23.22	19.07	28	23411	6868	29544220
Depression	23.21	19.07	20	23419	85127	29465961
Influenza	23.00	19.07	3	23436	41878	29509210
Anaphylactoid reaction	22.98	19.07	16	23423	1929	29549159
Abdominal discomfort	22.85	19.07	5	23434	47898	29503190
Pneumonitis	22.84	19.07	61	23378	27983	29523105
Hypovolaemic shock	22.68	19.07	26	23413	6046	29545042
Joint swelling	22.08	19.07	6	23433	49624	29501464
Bronchospasm	21.57	19.07	32	23407	9577	29541511
Unresponsive to stimuli	20.82	19.07	55	23384	25071	29526017
Cerebral ischaemia	20.60	19.07	24	23415	5679	29545409
Abdominal compartment syndrome	20.53	19.07	11	23428	828	29550260
Pelvic sepsis	20.52	19.07	4	23435	7	29551081
Metastases to liver	20.44	19.07	35	23404	11821	29539267
Enteritis	20.34	19.07	26	23413	6765	29544323
Metastases to lung	20.34	19.07	28	23411	7827	29543261
Overdose	20.27	19.07	20	23419	79799	29471289
Hypokalaemia	20.12	19.07	86	23353	50117	29500971
Butterfly rash	20.10	19.07	6	23433	93	29550995
Pneumonia aspiration	19.69	19.07	69	23370	36668	29514420
Lymphopenia	19.56	19.07	37	23402	13496	29537592
Muscle spasms	19.35	19.07	14	23425	65068	29486020
Diabetes mellitus	19.32	19.07	4	23435	39827	29511261
Ileal perforation	19.31	19.07	10	23429	702	29550386
Memory impairment	19.12	19.07	3	23436	36467	29514621
Cyanosis	19.08	19.07	33	23406	11234	29539854

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis acneiform	1117.10	18.70	326	29968	8117	64460321
Mucosal inflammation	443.90	18.70	307	29987	62277	64406161
Hypomagnesaemia	408.67	18.70	241	30053	37135	64431303
Skin toxicity	370.28	18.70	133	30161	6469	64461969
Dehydration	337.68	18.70	460	29834	216303	64252135
Malignant neoplasm progression	311.29	18.70	321	29973	112550	64355888
Neutropenia	300.75	18.70	459	29835	239165	64229273
Paronychia	291.25	18.70	111	30183	6381	64462057
Radiation skin injury	289.61	18.70	76	30218	1254	64467184
Infusion related reaction	275.75	18.70	362	29932	164105	64304333
Diarrhoea	246.56	18.70	820	29474	721884	63746554
Anaphylactic reaction	219.99	18.70	212	30082	68452	64399986
Rash	209.17	18.70	577	29717	457972	64010466
Stomatitis	201.98	18.70	253	30041	109352	64359086
Drug ineffective	177.68	18.70	87	30207	840160	63628278
Chills	144.42	18.70	243	30051	137021	64331417
Palmar-plantar erythrodysaesthesia syndrome	140.49	18.70	113	30181	28706	64439732
Arthralgia	132.49	18.70	24	30270	442236	64026202
Dysphagia	124.36	18.70	198	30096	106614	64361824
Dermatitis	105.97	18.70	79	30215	17950	64450488
Vomiting	104.86	18.70	523	29771	550594	63917844
Pharyngeal inflammation	101.29	18.70	31	30263	908	64467530
Skin fissures	101.00	18.70	62	30232	10244	64458194
Disease progression	100.54	18.70	212	30082	141468	64326970
Pulmonary embolism	99.26	18.70	215	30079	146141	64322297
Decreased appetite	98.47	18.70	323	29971	280966	64187472
Drug interaction	93.71	18.70	27	30267	362056	64106382
Thrombocytopenia	86.51	18.70	266	30028	223535	64244903
Skin reaction	83.69	18.70	59	30235	12293	64456145
Serous retinal detachment	83.69	18.70	25	30269	673	64467765
Leukopenia	83.12	18.70	161	30133	101081	64367357
Febrile neutropenia	82.97	18.70	234	30060	187423	64281015
Pyrexia	82.49	18.70	495	29799	558149	63910289
Hypocalcaemia	81	18.70	99	30195	41654	64426784
Metastases to lung	78.97	18.70	62	30232	15202	64453236
Nausea	78.73	18.70	633	29661	785167	63683271
Joint swelling	78.36	18.70	6	30288	215376	64253062
Neuropathy peripheral	77.77	18.70	171	30123	117354	64351084
Hypotension	77.61	18.70	369	29925	380605	64087833
Interstitial lung disease	77.29	18.70	153	30141	97579	64370859
Acne	77.13	18.70	73	30221	23008	64445430
Rash pustular	73.51	18.70	50	30244	9835	64458603
Peripheral swelling	72.88	18.70	7	30287	209146	64259292
Fall	72.56	18.70	54	30240	416772	64051666
Condition aggravated	71.88	18.70	43	30251	372383	64096055
Nasopharyngitis	69.83	18.70	6	30288	196067	64272371
Ileus	68.04	18.70	68	30226	22898	64445540
Hypokalaemia	67.09	18.70	165	30129	121738	64346700
Conjunctivitis	65.40	18.70	63	30231	20291	64448147
Pain in extremity	64.31	18.70	31	30263	303054	64165384
Neutrophil count decreased	63.63	18.70	123	30171	77073	64391365
Weight increased	60.78	18.70	13	30281	213335	64255103
Headache	60.74	18.70	97	30197	529370	63939068
Product dose omission issue	59.45	18.70	10	30284	194737	64273701
Dry skin	58.33	18.70	94	30200	51067	64417371
Radiation mucositis	58.01	18.70	14	30280	161	64468277
Erythema	57.63	18.70	206	30088	186864	64281574
Flushing	54.93	18.70	117	30177	78531	64389907
Pulse absent	54.36	18.70	40	30254	8906	64459532
Tumour haemorrhage	53.09	18.70	28	30266	3465	64464973
Hypersensitivity	52.74	18.70	207	30087	196245	64272193
Device related infection	50.51	18.70	67	30227	30559	64437879
Drug abuse	50.14	18.70	3	30291	132371	64336067
Metastases to liver	50.08	18.70	59	30235	23882	64444556
Onycholysis	49.37	18.70	21	30273	1605	64466833
Abdominal discomfort	48.21	18.70	13	30281	182309	64286129
Toxicity to various agents	47.15	18.70	61	30233	363452	64104986
Dyspnoea	45.92	18.70	527	29767	718147	63750291
White blood cell count decreased	45.37	18.70	170	30124	157667	64310771
Haematotoxicity	43.48	18.70	41	30253	12855	64455583
Drug intolerance	43.37	18.70	17	30277	187975	64280463
Anaemia	43.22	18.70	315	29979	378365	64090073
Therapeutic product effect decreased	42.54	18.70	3	30291	115348	64353090
Neoplasm progression	42.30	18.70	72	30222	40892	64427546
Insomnia	42.29	18.70	20	30274	197816	64270622
Enteritis	41.88	18.70	39	30255	12038	64456400
Sepsis	41.03	18.70	215	30079	230126	64238312
Musculoskeletal stiffness	40.67	18.70	5	30289	123201	64345237
Gait disturbance	40.66	18.70	15	30279	172140	64296298
Gastrointestinal toxicity	39.76	18.70	27	30267	5295	64463143
Sinusitis	39.35	18.70	10	30284	145918	64322520
Contusion	39.19	18.70	4	30290	113961	64354477
Product use issue	37.94	18.70	12	30282	151703	64316735
Pain	37.43	18.70	134	30160	553377	63915061
Blood magnesium decreased	37.24	18.70	39	30255	13866	64454572
Blood pressure immeasurable	36.90	18.70	18	30276	1890	64466548
Oesophagitis	36.72	18.70	48	30246	21582	64446856
Contraindicated product administered	36.53	18.70	4	30290	107825	64360613
Proteus infection	36.35	18.70	17	30277	1626	64466812
Deep vein thrombosis	34.22	18.70	118	30176	105064	64363374
Oxygen saturation decreased	33.80	18.70	119	30175	107057	64361381
Clostridial infection	33.63	18.70	24	30270	5095	64463343
Influenza	33.55	18.70	5	30289	106526	64361912
Nail dystrophy	33.24	18.70	13	30281	800	64467638
Pneumonitis	32.96	18.70	73	30221	50292	64418146
Drug hypersensitivity	32.82	18.70	38	30256	237777	64230661
Anaphylactic shock	32.23	18.70	54	30240	30274	64438164
Subileus	31.93	18.70	23	30271	4954	64463484
Necrotising oesophagitis	31.67	18.70	12	30282	678	64467760
Pneumatosis intestinalis	30.91	18.70	23	30271	5206	64463232
Laryngeal oedema	30.70	18.70	26	30268	7087	64461351
Bronchospasm	30.59	18.70	44	30250	21638	64446800
Cerebral ischaemia	30.43	18.70	30	30264	9932	64458506
Trichomegaly	29.05	18.70	7	30287	80	64468358
Asthma	28.80	18.70	5	30289	95220	64373218
Embolism	28.71	18.70	32	30262	12203	64456235
Prothrombin level decreased	28.68	18.70	14	30280	1472	64466966
Nail disorder	28.28	18.70	27	30267	8597	64459841
Neurotoxicity	28.07	18.70	48	30246	27356	64441082
Hepatic enzyme increased	27.97	18.70	13	30281	129930	64338508
Aspiration	27.93	18.70	37	30257	16848	64451590
Small intestinal obstruction	27.80	18.70	44	30250	23529	64444909
Bone marrow failure	27.51	18.70	66	30228	47886	64420552
Periorbital disorder	27.40	18.70	6	30288	43	64468395
Discomfort	27.39	18.70	3	30291	80875	64387563
Pneumonia aspiration	27.21	18.70	75	30219	59196	64409242
K-ras gene mutation	27.17	18.70	6	30288	45	64468393
Hyperbilirubinaemia	26.99	18.70	41	30253	21164	64447274
Staphylococcal infection	26.17	18.70	67	30227	50611	64417827
Blood pressure decreased	25.71	18.70	94	30200	86105	64382333
Intestinal obstruction	25.34	18.70	54	30240	36232	64432206
Anxiety	25.23	18.70	35	30259	202614	64265824
Hospitalisation	24.94	18.70	3	30291	75204	64393234
Monocytopenia	24.90	18.70	7	30287	151	64468287
Venous thrombosis	24.86	18.70	22	30272	6359	64462079
Overdose	24.82	18.70	23	30271	159543	64308895
Bronchitis	24.80	18.70	10	30284	108733	64359705
Myelosuppression	24.75	18.70	42	30252	23788	64444650
Colorectal cancer metastatic	24.59	18.70	11	30283	949	64467489
Induration	24.33	18.70	13	30281	1651	64466787
Cardio-respiratory arrest	24.23	18.70	101	30193	98292	64370146
Balance disorder	24.11	18.70	5	30289	83921	64384517
Swelling	23.87	18.70	24	30270	160194	64308244
Cardiac failure congestive	23.87	18.70	16	30278	130564	64337874
Gastrooesophageal reflux disease	23.79	18.70	5	30289	83138	64385300
Abdominal pain	23.51	18.70	237	30057	312138	64156300
Treatment failure	23.18	18.70	13	30281	116803	64351635
Wound	23.16	18.70	4	30290	76473	64391965
Memory impairment	22.84	18.70	6	30288	85676	64382762
Multiple-drug resistance	22.55	18.70	21	30273	6481	64461957
Ileal perforation	22.10	18.70	10	30284	886	64467552
Arthritis	22.10	18.70	6	30288	83808	64384630
Depression	21.49	18.70	33	30261	183258	64285180
Respiratory distress	20.90	18.70	63	30231	52268	64416170
Wrong technique in product usage process	20.57	18.70	3	30291	64971	64403467
Glossodynia	20.45	18.70	3	30291	64693	64403745
Abdominal compartment syndrome	20.44	18.70	11	30283	1417	64467021
Tachycardia	20.32	18.70	130	30164	149449	64318989
Carcinoembryonic antigen increased	20.24	18.70	12	30282	1861	64466577
Haemolytic uraemic syndrome	20.08	18.70	16	30278	4005	64464433
Lymphopenia	20.05	18.70	40	30254	25617	64442821
Osteoarthritis	19.88	18.70	3	30291	63333	64405105
Intentional product use issue	19.82	18.70	10	30284	95354	64373084
Hypertrichosis	19.74	18.70	10	30284	1138	64467300
Stress cardiomyopathy	19.67	18.70	23	30271	9234	64459204
Hallucination	19.59	18.70	5	30289	72783	64395655
Hypovolaemic shock	19.35	18.70	24	30270	10242	64458196
Nail toxicity	19.31	18.70	7	30287	349	64468089
Myalgia	19.14	18.70	28	30266	158589	64309849
Pruritus	18.89	18.70	227	30067	312173	64156265
Granulocyte count decreased	18.75	18.70	10	30284	1266	64467172

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FE01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES EGFR (Epidermal Growth Factor Receptor) inhibitors
FDA MoA	N0000020010	HER1 Antagonists
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000074322	Antineoplastic Agents, Immunological
FDA EPC	N0000175664	Epidermal Growth Factor Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Squamous cell carcinoma of mouth	indication	307502000
Rectal cancer with wild-type RAS	indication	363351006	DOID:1993
Malignant tumor of colon	indication	363406005	DOID:219
Squamous cell carcinoma of larynx	indication	405822008
Squamous cell carcinoma of pharynx	indication	408649007
Squamous cell carcinoma of nose	indication	448930008

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	ANTIBODY BINDING	Kd	9.41		IUPHAR	DRUG LABEL

External reference:

ID	Source
D03455	KEGG_DRUG
4021419	VUID
N0000148833	NUI
4021419	VANDF
CHEMBL1201577	ChEMBL_ID
6882	IUPHAR_LIGAND_ID
7906	INN_ID
DB00002	DRUGBANK_ID
PQX0D8J21J	UNII
14122979	PUBCHEM_CID
318341	RXNORM
17947	MMSL
48970	MMSL
d05101	MMSL
409400001	SNOMEDCT_US
409401002	SNOMEDCT_US
D000068818	MESH_DESCRIPTOR_UI
C0995188	UMLSCUI
008568	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ERBITUX	HUMAN PRESCRIPTION DRUG LABEL	1	66733-948	SOLUTION	2 mg	INTRAVENOUS	BLA	29 sections
ERBITUX	HUMAN PRESCRIPTION DRUG LABEL	1	66733-958	SOLUTION	2 mg	INTRAVENOUS	BLA	29 sections